ReviewPediatric research2026
Bilirubin: translational perspectives.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bilirubin reduces mortality in sepsis models by inhibiting NOX2-mediated formation of neutrophil extracellular traps.Redox report : communications in free radical research · 2026Article
- Label-Free Quantification of Bilirubin Using a Refractive Index-Insensitive Nanolaminate SERS Substrate.Biosensors · 2026Article
- Impact of maternal glycemic control during pregnancy on early biomarkers of neonatal metabolic syndrome.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilirubin, an old tetrapyrrolic compound that had occurred on Earth early on, is the final product of the catabolic heme pathway in the intravascular bed. Data from recent decades revealed its enormous bioactivity in a human body, including antioxidant, anti-inflammatory, immunosuppressive, antiproliferative, and even cell signaling activities that translate into beneficial effects of mildly elevated serum bilirubin concentrations resulting in prevention or amelioration of progression of many diseases of civilization. Furthermore, recent advances in bilirubin research have changed our understanding of bilirubin metabolism in the neonatal period, with discoveries of bilirubin reductase of bacterial origin in the intestinal lumen with direct pathophysiological and clinical implications. Similarly, our knowledge of the pathophysiology of neonatal jaundice phototherapy has improved substantially, although we are still at the beginning of the path to understand all the pathophysiological aspects and reveal related clinical implications. BULLET POINTS: Recent advances in our understanding of bilirubin metabolism with clear clinical implications, as well as other, so far putative, translational impacts. Demonstration of the beneficial biological potential of bilirubin, its evolutionary and ontogenetic functions, its possible role in chronobiology, and its correlation with increased fitness in elite athletes (a sort of gain of function). Discussion on the protective role of physiological neonatal jaundice. Inspiration for further basic and clinical research in specific fields of bilirubin metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.